INTRODUCTION
============

Sepsis is a syndrome of physiologic, pathologic, and biochemical abnormalities induced by infection that can result in multiple organ dysfunction via inflammatory cytokines, mitochondria dysfunction, and tissue hypoxia \[[@b1-acc-2020-00024]\]. Due to specific injury of cardiomyocytes, approximately 3.8%--65% of patients with sepsis develop sepsis-induced cardiomyopathy (SIC) \[[@b2-acc-2020-00024]-[@b7-acc-2020-00024]\]. SIC has been defined as myocardial dysfunction characterized by decreased ejection fraction (EF) and increased left ventricular end-diastolic diameter (LVEDD) that recovers within 7--10 days \[[@b2-acc-2020-00024]\]. Current understanding of the pathogenesis of SIC is limited, and conflicting results remain regarding the prognostic impact of SIC on sepsis outcomes.

Improved understanding of SIC is important for multiple reasons. First, cardiac function is crucial for maintaining hemodynamic stability in patients with septic shock. Second, by understanding the clinical features and predictors of SIC, we can discriminate SIC from other cardiac diseases and avoid unnecessary invasive procedures, such as coronary angiography, a risky procedure in critically ill patients. Thus, we aimed to define clinical predictors of SIC and assess the clinical course and outcome of SIC in patients with sepsis.

MATERIALS AND METHODS
=====================

Study Population
----------------

In this study, the medical records of patients who were admitted to the medical intensive care unit (ICU) of Yonsei University College of Medicine from June 2016 to September 2017 were reviewed. A total of 576 adult patients (\>18 years old) admitted to the ICU during this period were screened for inclusion ([Figure 1](#f1-acc-2020-00024){ref-type="fig"}). Patients who did not (1) meet the sepsis definition, (2) have baseline transthoracic echocardiography (TTE) data, or (3) undergo TTE within 48 hours after ICU admission were excluded. This study was approved by the Institutional Review Board and Ethics Committee of Severance Hospital (IRB No. 4-2018-0751). The requirement for written informed consent from patients was waived. All methods were performed in accordance with the Declaration of Helsinki.

Definitions of Variables
------------------------

The sepsis-3 definition was applied in patients with sepsis and septic shock \[[@b1-acc-2020-00024]\]. Sepsis was defined by an increase in Sequential Organ Failure Assessment (SOFA) score of ≥2 points due to infection. Infection was defined as detection of microorganisms in culture or as radiologic or clinical manifestations suggesting infection despite negative culture results \[[@b8-acc-2020-00024]\]. Septic shock was defined as sepsis with persistent hypotension requiring vasopressor drugs to maintain mean arterial pressure ≥65 mm Hg accompanied with serum lactate level \>2 mmol/L despite adequate volume resuscitation. Left ventricular function deterioration was defined as EF \<50% and ≥10% decrease in baseline EF. Among patients with left ventricular function deterioration, those whose EF recovered to the baseline level within 2 weeks were defined as having SIC \[[@b7-acc-2020-00024],[@b9-acc-2020-00024],[@b10-acc-2020-00024]\].

Data Collection
---------------

Demographic data (age, sex, body weight, height, pre-existing comorbidities), vital signs, laboratory findings, echocardiographic findings, and clinical findings (presence of acute kidney injury, acute respiratory distress syndrome, and use of mechanical ventilation) were collected. Laboratory tests were performed within 24 hours of ICU admission, and SOFA and Acute Physiology and Chronic Health Evaluation (APACHE) II scores were evaluated at ICU admission. The delta neutrophil index (DNI) was assessed using an automated blood cell analyzer (ADVIA 120; Siemens, Forchheim, Germany) and calculated using the following formula: (neutrophil subfraction+ eosinophil subfraction measured in the myeloperoxidase channel)--(polymorphonuclear subfraction measured in nuclear lobularity channel) \[[@b11-acc-2020-00024],[@b12-acc-2020-00024]\]. If there was no contraindication, TTE was routinely performed by a cardiologist at the time of ICU admission. There was no fixed schedule for follow up TTE, but in the majority of patients it was performed 1--2 weeks after ICU admission, especially when cardiac function deteriorated during ICU admission.

Statistical Analysis
--------------------

The primary endpoint was 28-day all-cause mortality of SIC. The secondary endpoint was to identify predictors of SIC development and risk factors for 28-day all-cause mortality in patients with SIC. Factors contributing to the incidence of SIC were also analyzed. Continuous variables were analyzed using Student t-test or Mann-Whitney U-test; categorical variables were analyzed using the chi-squared distribution and Fisher's exact test. A logistic regression model was used to identify variables contributing to the development of SIC. Cox proportional hazards regression analyses were conducted to assess the relationships between variables and 28-day allcause mortality. Area under the curve of receiver operating characteristic curves was used to identify the effect of major variables in multivariate Cox proportional hazards regression analysis (P\<0.05) on 28-day all-cause mortality. Cumulative time-to-event distribution (survival) was estimated using Kaplan-Meier survival curves, and differences in survival between groups were assessed using the log-rank test. In all cases, P-values \<0.05 were considered statistically significant. Statistical analyses were performed using R statistical software ver. 3.5.1 (R Foundation, Vienna, Austria).

RESULTS
=======

Baseline Characteristics of Study Population
--------------------------------------------

A total of 342 patients met the study eligibility criteria. Of these, 83 showed left ventricular function deterioration compared to baseline TTE. Among these, 49 patients had an EF that recovered to the baseline value and were categorized as SIC. Fifteen patients with persistently decreased EF in follow-up TTE and 19 patients without follow-up TTE were excluded ([Figure 1](#f1-acc-2020-00024){ref-type="fig"}). A total of 259 patients whose EF did not deteriorate with sepsis were categorized as the non-SIC group.

Baseline characteristics of 49 SIC and 259 non-SIC patients with sepsis are shown in [Table 1](#t1-acc-2020-00024){ref-type="table"}. There was no significant difference between SIC and non-SIC patients in terms of age, sex, and body mass index. APACHE II and SOFA scores also did not significantly differ between SIC and non-SIC patients. Underlying heart failure was more frequent in SIC patients (8.2% vs. 1.5%, P=0.029), but the incidence of other comorbidities, including coronary artery disease, was not significantly different between the groups. On ICU admission, systolic blood pressure was significantly lower in patients with SIC (83.9±18.3 vs. 91.1±22.9, P=0.039). There was no significant difference in vasopressor and inotrope use between SIC and non-SIC patients. Primary site of infection was not significantly different between SIC and non-SIC patients. Both C-reactive protein and serum bilirubin levels were higher (192.4± 134.2 vs. 137.5±110.6, P=0.002; 1.2±1.4 vs. 2.1±4.1, P=0.008, respectively), whereas serum albumin levels were lower (2.4± 0.5 vs. 2.5±0.5, P=0.032) in SIC patients than in non-SIC patients.

Echocardiographic findings and cardiac biomarkers are shown in [Table 2](#t2-acc-2020-00024){ref-type="table"}. LVEDD and left ventricular end-systolic diameter (LVESD) were significantly increased in SIC patients (49.6±6.0 vs. 43.4±6.3, P\<0.001; 39.5±6.4 vs. 28.7±4.8, P\<0.001, respectively). N-terminal pro b-type natriuretic peptide (NTproBNP; pg/ml) and troponin-T (pg/ml) were significantly higher in SIC patients (19,911.2±18,194.9 vs. 7,940.3±13,613.9, P\<0.001; 278.9±492.7 vs. 104.8±178.4, P=0.019, respectively), but creatine kinase (CK) and creatine kinase-muscle/brain (CK-MB) levels were not significantly different between SIC and non-SIC patients.

Predictors of SIC
-----------------

Univariate logistic regression analyses for predictors of SIC revealed that low systolic blood pressure, hypoalbuminemia, elevated NT-proBNP, troponin-T, and increased LVEDD were major covariates (P\<0.05). Multivariate logistic regression analysis revealed that low systolic blood pressure upon ICU admission and increased LVEDD were independent risk factors for the development of SIC ([Table 3](#t3-acc-2020-00024){ref-type="table"}).

Outcomes of SIC
---------------

There was no significant difference between SIC patients and non-SIC patients in 28-day all-cause mortality (24.5% vs. 26.3%, P=0.936), length of ICU stay in days (15.4±13.8 vs. 12.4±20.2, P=0.249), ICU mortality (26.5% vs. 24.3%, P=0.882), and inhospital mortality (36.7% vs 36.7%, P=1.000) ([Table 4](#t4-acc-2020-00024){ref-type="table"}). Among 31 patients who survived in the hospital, 25 were discharged home and six were transferred to another hospital. Cause of death for those who died in the hospital were as follows: primary infection-related multiple organ failure (n=10), respiratory failure (n=3), end of life decision (n=4), sudden cardiac arrest (n=1).

SIC patients were divided into survivors and non-survivors according to 28-day all-cause mortality, as shown in [Table 5](#t5-acc-2020-00024){ref-type="table"}. Non-survivors showed higher APACHE II (32.1±8.3 vs. 24.4± 8.9, P=0.012) and SOFA scores (11.7±3.3 and 9.1±3.0, P=0.015) than survivors. Non-survivors showed significantly lower platelet counts (54.0; interquartile range \[IQR\], 29.0--138.5 vs. 155.0; IQR, 76.0--271.0; P=0.024) and higher DNI (26.1; IQR, 3.0--45.9 vs. 3.2; IQR, 1.1--9.5; P=0.049) than survivors. Regarding vital signs on admission, non-survivors showed a higher heart rate than survivors (134.3±25.8 vs. 101.5±25.2, P\<0.001). Cox hazard proportional regression analysis for 28-day mortality in SIC patients revealed that APACHE II (hazard ratio \[HR\], 1.10; 95% confidential interval \[CI\], 1.02 to 1.18; P=0.009) and DNI (HR, 1.02; 95% CI, 1.00 to 1.08; P=0.026) were independent risk factors, while TEE parameters and cardiac biomarkers did not show statistically significant correlations with 28- day mortality. Cox hazard proportional regression analysis for 28-day mortality in sepsis patients as a whole revealed that APACHE II (HR, 1.04; 95% CI, 1.01 to 1.07; P=0.004), DNI (HR, 1.02; 95% CI, 1.00 to 1.03; P=0.044), and lactate (HR, 1.07; 95% CI, 1.02 to 1.13; P=0.007) were independent risk factors ([Table 6](#t6-acc-2020-00024){ref-type="table"}). These variables are known to represent sepsis severity \[[@b12-acc-2020-00024]-[@b14-acc-2020-00024]\]. This suggests that sepsis severity, rather than TTE parameters and cardiac biomarkers, has the most important effect on SIC mortality.

Using the definition of SIC delineated in this study, patients with reversible LV function deterioration due to sepsis were compared with non-SIC patients. Of 83 patients who showed LV function deterioration, 15 patients with persistent LV dysfunction in follow-up TTE and 19 patients without follow-up TTE were excluded. The mortality outcomes of these two excluded groups are shown in [Figure 1](#f1-acc-2020-00024){ref-type="fig"}. While patients with persistent LV dysfunction revealed similar mortality outcomes as SIC and non-SIC patients, the group of patients without follow-up TTE showed a significantly poorer mortality outcome (28-day mortality, 73.7%). Follow-up TTE data were not available within 14 days from the first TTE in this group of patients for the following reasons. Eight patients (42.1%) died within 72 hours after ICU admission, end-of-life decisions were made for six patients (31.6%) mostly due to terminal underlying diseases (e.g., cancer), two patients were transferred to other hospitals, and three patients (15.8%) recovered from sepsis.

DISCUSSION
==========

In this study, we demonstrated the clinical features, predictors, and survival outcomes of SIC. Low systolic blood pressure and increased LVEDD were revealed to be independent predictors of SIC. There was no significant difference between SIC and sepsis patients as a whole in terms of 28-day all-cause mortality. However, high APACHE II scores and DNI, which reflect sepsis severity, were independent risk factors for 28-day all-cause mortality in SIC patients.

To define SIC, we used a definition commonly applied in previous studies \[[@b2-acc-2020-00024],[@b7-acc-2020-00024],[@b10-acc-2020-00024]\]. In these studies, the inclusion of preexisting cardiac diseases was controversial. In some studies, patients with pre-existing cardiac disease were excluded to reduce false-positive errors in detecting SIC \[[@b4-acc-2020-00024],[@b5-acc-2020-00024],[@b10-acc-2020-00024],[@b15-acc-2020-00024]-[@b17-acc-2020-00024]\]. However, those with pre-existing cardiac disease should be included and evaluated if this condition alters the risk of SIC development and survival. Our study revealed that neither heart failure nor coronary artery disease was a risk factor for SIC development or mortality.

Recently, several studies have indicated differences in the pathophysiology of SIC and stress-induced cardiomyopathy, also known as Takotsubo cardiomyopathy, in which sepsis is the source of stress \[[@b7-acc-2020-00024],[@b9-acc-2020-00024],[@b10-acc-2020-00024]\]. Endotoxins, inflammatory cytokines, and nitric oxides are major contributors to the development of SIC \[[@b18-acc-2020-00024],[@b19-acc-2020-00024]\]. In contrast, elevated catecholamine release is a key contributor to the development of Takotsubo cardiomyopathy \[[@b20-acc-2020-00024]\]. However, it is difficult to distinguish these two diseases based on clinical parameters. Previous studies that distinguished SIC and Takotsubo cardiomyopathy used the criterion of typical apical ballooning in TTE. However, Takotsubo cardiomyopathy has both apical ballooning type and atypical type, which are difficult to discriminate from SIC based on TTE findings \[[@b20-acc-2020-00024],[@b21-acc-2020-00024]\]. Thus, we proposed that SIC is a syndrome characterized by reversible LV dysfunction and includes Takotsubo cardiomyopathy caused by sepsis. Endotoxins, inflammatory cytokines, nitric oxides, and catecholamine are all considered associated with SIC development.

Echocardiography revealed that LVEDD was significantly higher in SIC patients than in non-SIC patients. Diastolic ventricle size increased to compensate for decreased systolic contractility. After fluid resuscitation, stroke volume can recover while EF is temporarily decreased due to increased LVEDD. Based on this pathophysiology, the importance of diastolic dysfunction rather than systolic function has been emphasized recently with reports of correlation between a lower e', higher E/e' ratio, and mortality in sepsis patients \[[@b19-acc-2020-00024],[@b22-acc-2020-00024]\]. However, in this study, the LVEDD and E/e' ratio did not show significant differences between survivors and non-survivors. This might be due to missing TTE parameters, especially in non-survivors.

In this study, low systolic blood pressure upon ICU admission and increased LVEDD were considered predictors of SIC development. Low systolic blood pressure resulting in inadequate coronary blood flow has been proposed as a mechanism of SIC based on animal studies \[[@b23-acc-2020-00024]\]. Dilated LVEDD is diastolic compliance to decreased systolic function \[[@b19-acc-2020-00024]\]. The predictors of SIC identified in this study are discrepant from those previously identified, probably due to the small sample size of each study and the use of discordant definitions \[[@b7-acc-2020-00024],[@b10-acc-2020-00024],[@b24-acc-2020-00024]\].

In SIC patients, tachycardia on ICU admission was significantly more common among non-survivors than survivors. This is explained by adapting to insufficient diastolic filling to increase stroke volume. In the Cox proportional hazard regression analysis of 28-day mortality, APACHE II score and DNI were revealed as independent risk factors for mortality in SIC patients. Both APACHE II and DNI are markers of sepsis severity. DNI is a novel biomarker that reflects the number of circulating granulocytes in blood and correlates with sepsis severity in critically ill patients \[[@b11-acc-2020-00024],[@b12-acc-2020-00024],[@b25-acc-2020-00024],[@b26-acc-2020-00024]\]. This suggests that sepsis severity has a greater effect on SIC prognosis than TEE parameters and cardiac biomarkers.

Among the 83 patients who showed LV dysfunction, 19 had no follow-up TTE. This group of patients showed significantly poorer mortality outcome, suggesting that the cardiac function of these 19 patients deteriorated due to sepsis and they usually did not recover, resulting in mortality. This may imply that this group of patients had the same pathophysiology as patients with SIC development and poor outcome. Due to the small number of these patients, the characteristics of persistent LV dysfunction could not be analyzed in detail in this group with no follow-up TTE. Further studies should be performed to clarify the characteristics of these patients.

This study had several limitations. First, detailed information regarding fluid resuscitation and vasopressor initiation were not available. These factors strongly affect sepsis patient prognosis. However, the study was performed in a single ICU of a tertiary university hospital in which sepsis management, including fluid resuscitation and vasopressor initiation, was generally performed according to the more recent sepsis-3 guidelines. Second, baseline TTE and TTE within 48 hours were not available in 8.7% of the initial population. This selection bias may have influenced the final results. Third, TTE parameters were not documented equally among patients and laboratory data. For example, inflammatory cytokines and catecholamines were not available due to the retrospective nature of this study. Lastly, this was a single center, retrospective study, which could affect the generalizability of results. Further prospective studies are needed to validate the results of this study.

In conclusion, this study identified predictors and outcome of SIC with inclusion of pre-existing cardiac diseases and Takotsubo cardiomyopathy. We found that low systolic blood pressure and dilated LVEDD were SIC predictors. The prognosis of SIC was affected by sepsis severity rather than cardiac function. Reversible SIC does not increase mortality risk compared to non-SIC. Further studies are needed on sepsis patients with persistent LV dysfunction and on patients whose LV function could not be restored, resulting in death.

KEY MESSAGES
============

▪ Sepsis-induced cardiomyopathy (SIC) occurred in 14.3% of intensive care unit patients with sepsis.

▪ Low systolic blood pressure and increased left ventricular end-diastolic diameter were predictors of SIC.

▪ High Acute Physiology and Chronic Health Evaluation II and elevated delta neutrophil index were risk factors of 28-day mortality in SIC.
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![Patient recruitment flowchart. ICU: intensive care unit; TTE: transthoracic echocardiography; LV: left ventricle; SIC: sepsis-induced cardiomyopathy. ^a^Patients without follow-up TTE showed poor mortality outcome. Lack of follow-up TTE in this group was due to several reasons: eight patients (42.1%) died within 72 hours after ICU admission, end-of-life decisions were made for six patients (31.6%), two patients were transferred to other hospitals, and three patients (15.8%) recovered from sepsis.](acc-2020-00024f1){#f1-acc-2020-00024}

###### 

Baseline characteristics of patients

  Variable                          Total (n=308)   SIC (n=49)    Non-SIC (n=259)   P-value
  --------------------------------- --------------- ------------- ----------------- ---------
  Age (yr)                          64.6±14.5       65.1±11.2     64.6±15.0         0.772
  Male sex                          195 (63.3)      32 (65.3)     163 (62.9)        0.877
  BMI (kg/m^2^)                     22.2±4.3        22.4±3.9      22.2±4.4          0.782
  APACHE II                         24.9±8.8        26.4±9.3      24.6±8.6          0.209
  SOFA                              9.4±3.2         9.7±3.2       9.3±3.2           0.378
  Comorbidity                                                                       
   Hypertension                     159 (51.6)      25 (51.0)     134 (51.7)        1.000
   Diabetes mellitus                108 (35.1)      17 (34.7)     91 (35.1)         1.000
   Chronic kidney disease           67 (21.8)       11 (22.4)     56 (21.6)         1.000
   Liver cirrhosis                  25 (8.1)        2 (4.1)       23 (8.9)          0.399
   Chronic liver disease            29 (9.4)        1 (2.0)       28 (10.8)         0.097
   Cancer                           83 (26.9)       16 (32.7)     67 (25.9)         0.420
   Heart failure                    8 (2.6)         4 (8.2)       4 (1.5)           0.029
   Coronary artery disease          30 (9.7)        7 (14.3)      23 (8.9)          0.364
   Cerebrovascular disease          42 (13.6)       6 (12.2)      36 (13.9)         0.934
  Charlson comorbidity index        2.8±2.2         3.2±2.1       2.8±2.2           0.231
  Acute kidney injury               73 (23.7)       14 (28.6)     59 (22.8)         0.490
  ARDS                              28 (9.1)        8 (16.3)      20 (7.7)          0.099
  Septic shock                      295 (95.8)      49 (100.0)    246 (95.0)        0.224
  Blood culture (+)                 113 (36.7)      22 (44.9)     91 (35.1)         0.255
  Mechanical ventilation            200 (64.9)      36 (73.5)     164 (63.3)        0.229
  Vital sign on admission                                                           
   SBP (mm Hg)                      90.0±22.3       83.9±18.3     91.1±22.8         0.039
   MAP (mm Hg)                      66.7±15.4       64.3±15.3     67.1±15.4         0.249
   HR (bpm)                         103.0±27.9      109.6±28.9    101.7±27.6        0.071
  Use of vasopressor and inotrope                                                   
   None                             13 (4.2)        0             15 (5.1)          0.224
   Norepinephrine                   262 (85.1)      44 (89.8)     247 (84.3)        0.420
   Dobutamine                       3 (0.9)         2 (4.1)       1 (0.4)           0.105
  Primary focus of infection                                                        0.507
   Pulmonary                        155 (50.3)      29 (59.2)     126 (48.6)        
   GI tract                         43 (14.0)       3 (6.1)       40 (15.4)         
   Urogenital                       35 (11.4)       7 (14.3)      28 (10.8)         
   Pancreatobiliary                 25 (8.1)        2 (4.1)       23 (8.9)          
   Soft tissue/bone                 17 (5.5)        4 (8.2)       13 (5.0)          
   Liver                            9 (2.9)         1 (2.0)       8 (3.1)           
   Kidney                           6 (1.9)         1 (2.0)       5 (1.9)           
   Miscellaneous                    18 (5.8)        2 (4.1)       16 (6.2)          
  Laboratory parameter                                                              
   WBC (10^3^/µl)                   15.1±10.4       12.9±10.3     15.5±10.4         0.117
   Platelet (10^3^/µl)              159.2±120.4     162.6±139.1   158.5±116.8       0.831
   Serum albumin (g/dl)             2.5±0.5         2.4±0.5       2.5±0.5           0.032
   Serum bilirubin (mg/dl)          2.0±3.8         1.2±1.4       2.1±4.1           0.008
   Serum creatinine (mg/dl)         2.1±1.9         2.0±1.8       2.1±2.0           0.757
   Lactate (mmol/L)                 4.0±4.1         3.8±3.4       4.0±4.3           0.826
   CRP                              146.3±116.2     192.4±134.2   137.5±110.6       0.002
   Procalcitonin (ng/ml)            17.5±33.0       23.9±35.5     16.2±32.4         0.135
   DNI (%)                          11.0±15.1       13.9±18.9     10.5±14.2         0.224

Values are presented as mean±standard deviation or number (%).

SIC: sepsis-induced cardiomyopathy; BMI: body mass index; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; ARDS: acute respiratory distress syndrome; SBP: systolic blood pressure; MAP: mean arterial pressure; HR: heart rate; GI: gastrointestinal; WBC: white blood cell; CRP: C-reactive protein; DNI: delta neutrophil index.

###### 

Echocardiographic parameters and cardiac biomarkers of patients

  Echocardiographic parameter   SIC (n=49)   Non-SIC (n=259)     P-value                      
  ----------------------------- ------------ ------------------- --------- ------------------ ---------
  Ejection fraction (%)         49           34.3±8.4            259       64.7±7.5           \<0.001
   LVEDD (mm)                   46           49.6±6.0            248       43.4±6.3           \<0.001
   LVESD (mm)                   46           39.5±6.4            248       28.7±4.8           \<0.001
   Mitral E/e' ratio            36           12.9±5.5            198       12.0±4.3           0.341
   FAC (%)                      7            25.3±5.3            17        24.0±8.7           0.712
  Cardiac biomarker                                                                           
   NT-proBNP (pg/ml)            46           19,911.2±18,194.9   233       7,940.3±13,613.9   \<0.001
   CK (IU/L)                    49           341.7±491.8         245       635.9±3,711.8      0.235
   CK-MB (ng/ml)                49           8.0±12.8            252       11.9±60.3          0.357
   Troponin-T (pg/ml)           48           278.9±492.7         230       104.8±178.4        0.019

Values are presented as mean±standard deviation.

SIC: sepsis-induced cardiomyopathy; LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter; E: early mitral inflow velocity; e': mitral annular early diastolic velocity; FAC: fractional area change; NT-proBNP: N-terminal pro b-type natriuretic peptide; CK: creatine kinase; CK-MB: creatine kinase-muscle/brain.

###### 

Logistic regression analyses for predictors of sepsis induced cardiomyopathy

  Variable                                    HR (95% CI)          P-value
  ------------------------------------------- -------------------- ---------
  Univariate logistic regression analysis                          
   Age                                        0.99 (0.97--1.02)    0.714
   Male sex                                   0.73 (0.31--1.70)    0.460
   Diabetes mellitus                          0.59 (0.25--1.38)    0.221
   Heart failure                              4.79 (0.29--78.86)   0.273
   Systolic blood pressure                    0.98 (0.96--1.00)    0.027
   Heart rate                                 1.00 (0.98--1.01)    0.748
   CRP                                        1.00 (1.00--1.01)    0.088
   Procalcitonin                              1.01 (0.99--1.02)    0.357
   DNI                                        1.00 (0.97--1.02)    0.821
   Lactate                                    0.93 (0.83--1.05)    0.264
   Albumin                                    0.43 (0.20--0.94)    0.035
   Blood culture (+)                          1.28 (0.57--2.87)    0.553
   NT-proBNP/1000                             1.03 (1.01--1.06)    0.001
   Troponin T/10                              1.03 (1.01--1.06)    0.007
   LVEDD                                      1.19 (1.09--1.28)    \<0.001
   E/e'                                       1.05 (0.97--1.14)    0.195
  Multivariate logistic regression analysis                        
   Systolic blood pressure                    0.96 (0.93--0.99)    0.007
   Albumin                                    0.38 (0.14--1.07)    0.066
   NT-proBNP/1000                             1.04 (0.99--1.04)    0.296
   Troponin T/10                              1.01 (1.00--1.03)    0.068
   LVEDD                                      1.24 (1.13--1.37)    \<0.001

HR: hazard ratio; CI: confidential interval; CRP: c-reactive protein; DNI: delta neutrophil index; NT-proBNP: N-terminal pro b-type natriuretic peptide; LVEDD: left ventricular end-diastolic diameter; E: early mitral inflow velocity; e': mitral annular early diastolic velocity.

###### 

Outcome of sepsis induced cardiomyopathy

  Variable                   Total (n=308)   SIC (n=49)   Non-SIC (n=259)   P-value
  -------------------------- --------------- ------------ ----------------- ---------
  28-Day mortality           80 (26.0)       12 (24.5)    68 (26.3)         0.936
  In-hospital mortality      113 (36.7)      18 (36.7)    95 (36.7)         1.000
  ICU mortality              76 (24.7)       13 (26.5)    63 (24.3)         0.882
  Length of ICU stay (day)   13.2±19.3       15.4±13.8    12.7±20.2         0.249

Values are presented as number (%) or mean±standard deviation.

SIC: sepsis-induced cardiomyopathy; ICU: intensive care unit.

###### 

Baseline characteristics of sepsis-induced cardiomyopathy patients according to 28-day all-cause mortality

  Characteristics                    Survivor (n=37)                       Non-survivor (n=12)                   P-value
  ---------------------------------- ------------------------------------- ------------------------------------- ---------
  Age (yr)                           65.0±11.2                             65.3±11.7                             0.935
  Male sex                           24 (64.9)                             8 (66.7)                              1.000
  BMI (kg/m^2^)                      22.3±3.8                              22.6±4.3                              0.837
  APACHE II                          24.4±8.9                              32.1±8.3                              0.012
  SOFA                               9.1±3.0                               11.7±3.3                              0.015
  Charlson comorbidity index         3.0 (2.0--4.0)                        3.0 (2.0--4.5)                        0.715
  Acute kidney injury                10 (27.0)                             4 (33.3)                              0.721
  ARDS                               8 (21.6)                              0                                     0.173
  Mechanical ventilation             25 (67.6)                             11 (91.7)                             0.142
  Blood culture (+)                  16 (43.2)                             6 (50.0)                              0.940
  Vital sign on admission                                                                                        
   Systolic blood pressure (mm Hg)   83.7±18.5                             84.7±18.3                             0.876
   Mean arterial pressure (mm Hg)    64.8±15.1                             63.1±16.7                             0.746
   Heart rate (bpm)                  101.5±25.2                            134.3±25.8                            \<0.001
  Use of vasopressor                                                                                             
   Norepinephrine                    32 (86.5)                             12 (100.0)                            0.427
   Dobutamine                        2 (5.4)                               0                                     1.000
  Laboratory parameter                                                                                           
   WBC (10^3^/µl)                    10.3 (7.0--17.1)                      9.4 (3.0--14.7)                       0.429
   Platelet (10^3^/µl)               155.0 (76.0--271.0)                   54.0 (29.0--138.5)                    0.024
   Serum albumin (g/dl)              2.4±0.6                               2.4±0.5                               0.872
   Serum bilirubin (mg/dl)           0.7 (0.4--1.1)                        1.0 (0.4--1.9)                        0.470
   Serum creatinine (mg/dl)          1.3 (0.9--1.9)                        2.0 (1.2--3.6)                        0.212
   Lactate (mmol/L)                  2.5 (1.6--3.8)                        4.0 (2.0--7.6)                        0.089
   CRP                               179.1 (100.7--257.4)                  185.9 (49.5--343.2)                   1.000
   Procalcitonin (ng/ml)             5.1 (1.3--30.3)                       5.6 (0.8--40.6)                       0.917
   DNI (%)                           3.2 (1.1--9.5)                        26.1 (3.0--45.9)                      0.049
  Echocardiographic finding                                                                                      
   Ejection fraction (%)             34.9±8.7                              32.6±7.5                              0.410
   LVEDD (mm)                        50.2±5.1 (n=35)                       47.6±8.1 (n=11)                       0.339
   LVESD (mm)                        39.7±5.8 (n=35)                       39.1±8.2 (n=11)                       0.800
   Mitral E/e' ratio                 12.9±4.8 (n=31)                       13.2±10.0 (n=5)                       0.943
  Cardiac biomarker                                                                                              
   NT-proBNP (pg/ml)                 11,983.0 (7,514.5--30,442.0) (n=35)   22,073.0 (3,705.5--35,000.0) (n=11)   0.857
   CK (IU/L)                         76.0 (35.0--331.0)                    171.0 (59.0--688.0)                   0.231
   CK-MB (ng/ml)                     4.2 (2.0--7.2)                        2.1 (1.5--5.3)                        0.236
   Troponin-T (pg/ml)                156.0 (47.0--318.0)                   108.0 (62.5--304.0) (n=11)            0.980

Values are presented as mean±standard deviation, number (%), or median (interquartile range).

BMI: body mass index; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; ARDS: acute respiratory distress syndrome; WBC: white blood cell; CRP: C-reactive protein; DNI: delta neutrophil index; LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter; E: early mitral inflow velocity; e': mitral annular early diastolic velocity; NT-proBNP: N-terminal pro b-type natriuretic peptide; CK: creatine kinase; CK-MB: creatine kinase-muscle/brain.

###### 

Cox proportional hazard regression analysis for 28-day mortality in SIC patients and sepsis patients as a whole

  Variable                     Univariate            Multivariate                       
  ---------------------------- --------------------- -------------- ------------------- -------
  SIC patient                                                                           
   APACHE II                   1.08 (1.02--1.14)     0.006          1.10 (1.02--1.18)   0.009
   DNI                         1.03 (0.01--2.21)     0.027          1.02 (1.00--1.08)   0.026
   Lactate                     1.12 (1.01--1.24)     0.036          1.12 (0.74--1.07)   0.210
   EF                          0.97 (0.91--1.04)     0.381                              
   LVEDD                       0.94 (0.85--1.04)     0.231                              
  Sepsis patients as a whole                                                            
   APACHE II                   1.06 (1.03--1.09)     \<0.001        1.04 (1.01--1.07)   0.004
   DNI                         1.03 (0.01--1.04)     \<0.001        1.02 (1.00--1.03)   0.044
   Lactate                     1.12 (1.07--1.16)     \<0.001        1.07 (1.02--1.13)   0.007
   EF                          1.01 (0.99--1.03)     0.321                              
   LVEDD                       0.96 (0.93--0.98)     0.008          0.97 (0.93--1.01)   0.118
   SIC                         0.89 (0.0.48--1.65)   0.723          0.88 (0.43--1.74)   0.688

SIC: sepsis-induced cardiomyopathy; HR: hazard ratio; CI: confidential interval; APACHE: Acute Physiology and Chronic Health Evaluation; DNI: delta neutrophil index; EF: ejection fraction; LVEDD: left ventricular enddiastolic diameter.
